Skip to Content
DAEWOONG PHARMACEUTICAL CO.LTD.
About Daewoong
About Daewoong
Global Network
Company Culture
History
Ethics
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
CTD List
Newsroom
Press Release
PR Videos
Investors
Overview
Corperate Governance
Annual Reports
Stock Info
IR
Careers
EN
KR
EN
View all menu
About Daewoong
About Daewoong
Our Purpose
CEO Message
Affiliates
Global Network
Company Culture
History
Ethics
Compliance Program
CEO Message
CP Rating
CP Activities
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing
Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
CTD List
Newsroom
Press Release
PR Videos
Investors
Overview
Corperate Governance
Overview
Board of Directors
Stockholder Info
Stockholder's meeting
Annual Reports
Balance Sheet
Income Statement
Credit Rating
Stock Info
Stock Info
Stock Status
IR
Events
IR Letter
Earnings announcement
Analysis Data
FAQ
Careers
Daewoong
Global Healthcare Group
The Best Partner for You
Press Release
Daewoong Pharmaceutical’s press release
NEW
1
Daewoong Pharmaceutical’s gastroesophageal reflux disease drug Fexuprazan obtained approval for a phase-3 trial in China
2020-12
30
NEW
2
Daewoong Pharmaceutical’s Nabota proves its efficacy in hair loss through clinical trials
2020-11
25
NEW
3
Daewoong Pharmaceutical’s Foistar Tab expected to be released as treatment for COVID-19 in January 2021
2020-11
23
Daewoong Pharmaceutical’s gastroesophageal reflux disease drug Fexuprazan obtained approval for a phase-3 trial in China
2020-12-30
Daewoong Pharmaceutical’s Nabota proves its efficacy in hair loss through clinical trials
2020-11-25
Daewoong Pharmaceutical’s Foistar Tab expected to be released as treatment for COVID-19 in January 2021
2020-11-23
Daewoong Pharmaceutical’s subsidiary iN Therapeutics begins development of hearing loss treatment with AI drug company DEARGEN Inc.
2020-11-17
Daewoong Pharmaceutical’s Olostar proved its excellent blood pressure reduction effects… Published in an SCI-grade journal
2020-11-11
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study
2020-11-06
Daewoong Pharmaceutical obtains approval for phase-3 clinical trials in South Korea for third indications of new drug Enavogliflozin for diabetes treatment
2020-11-04
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide
2020-10-29
Daewoong Pharmaceutical’s Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 ‘Twindemic’
2020-10-27
1
2
3
4
5
6
7
8
9
10
다음 페이지
Search
search word
Delete
Search